Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Primer extension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Primer extension. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-001338-33 Sponsor Protocol Number: TOPMAT-PEP-3001 Start Date*: 2006-01-20
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concur...
    Medical condition: Partial Onset Epilepsy and other Seizures
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) NO (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018412-32 Sponsor Protocol Number: DMD114117 Start Date*: 2010-08-05
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambul...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) FR (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005042-35 Sponsor Protocol Number: PRO053-CLIN-01 Start Date*: 2013-08-23
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053)...
    Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by BMN 053-induced DMD exon 53 skipping
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-015816-17 Sponsor Protocol Number: NN1250-3667 Start Date*: 2010-07-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: An extension trial to NN1250-3582 comparing safety and efficacy of NN1250 and insulin glargine, both with insulin aspart as meal-time insulin ± OADs in type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) ES (Completed) IT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005320-81 Sponsor Protocol Number: CACZ885A2201E2 Start Date*: 2008-10-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid ar...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014660-19 Sponsor Protocol Number: RDEA594-203 Start Date*: 2009-12-09
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients w...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004954-34 Sponsor Protocol Number: 28981 Start Date*: 2008-12-12
    Sponsor Name:Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin...
    Medical condition: Subjects of high risk of converting to Multiple Sclerosis or subjects already converted to Multiple Sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) FI (Completed) ES (Completed) PT (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) GR (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000949-11 Sponsor Protocol Number: 0683-014 Start Date*: 2005-07-06
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated Wit...
    Medical condition: Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027406 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014490-41 Sponsor Protocol Number: AC-065A302 Start Date*: 2010-02-22
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multicenter, double-blind, placebo-controlled Phase 3 study assessing the safety and efficacy of selexipag on morbidity and mortality in patients with pulmonary arterial hypertension
    Medical condition: The intended indication is Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) FR (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) IE (Completed) HU (Completed) AT (Completed) SK (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019550-40 Sponsor Protocol Number: AMAG-FER-CKD-253 Start Date*: Information not available in EudraCT
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Temporarily Halted) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015754-38 Sponsor Protocol Number: NN1250-3643 Start Date*: 2010-04-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: An extension trial to NN1250-3579 comparing safety and efficacy of NN1250 plus OAD(s) with insulin glargine plus OAD(s) in type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) CZ (Completed) FI (Completed) DK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002345-23 Sponsor Protocol Number: A3921050 Start Date*: 2008-11-28
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA
    Full Title: A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS
    Medical condition: Prevention of kidney allograft rejection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10066543 Acute allograft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed) BE (Completed) NL (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-002999-34 Sponsor Protocol Number: Y-79-52120-126 Start Date*: 2007-12-04
    Sponsor Name:Ipsen Limited
    Full Title: A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one ...
    Medical condition: Idiopathic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019497-32 Sponsor Protocol Number: PGL09-027 Start Date*: 2010-11-09
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatme...
    Medical condition: Uterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly as...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) PL (Completed) AT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017251-94 Sponsor Protocol Number: P09-09/BF2.649 Start Date*: 2011-02-21
    Sponsor Name:Bioprojet
    Full Title: Efficacy and safety of BF2.649 in the treatment of Excessive Daytime Sleepiness in patients with Obstructive Sleep Apnoea syndrome (OSA), refusing the nasal continuous positive airway pressure (nCP...
    Medical condition: Excessive diurnal sleepiness in patients with moderate to severe Obstructive Sleep Apnoea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10015595 Excessive daytime sleepiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FI (Completed) SE (Completed) DK (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-003226-19 Sponsor Protocol Number: MS-LAQ-301 Start Date*: 2007-09-05
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laq...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) GB (Completed) FR (Completed) CZ (Completed) LV (Completed) AT (Completed) LT (Completed) ES (Completed) EE (Completed) PT (Prematurely Ended) SE (Completed) IT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018999-25 Sponsor Protocol Number: PGL09-026 Start Date*: 2010-07-13
    Sponsor Name:PregLem S.A.
    Full Title: Estudio multicéntrico de fase III para investigar la eficacia y la seguridad del tratamiento abierto de 3 meses con PGL4001, seguido de un periodo aleatorizado, doble ciego y controlado con placebo...
    Medical condition: Los miomas uterinos son tumores benignos, monoclonales y sensibles a las hormonas, del músculo liso del útero. Son los miomas que aparecen con más frecuencia en el aparato reproductor femenino en l...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) PL (Completed) AT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013174-41 Sponsor Protocol Number: CRPC2 Start Date*: 2009-10-14
    Sponsor Name:Medivation, Inc.
    Full Title: AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously ...
    Medical condition: Patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) GB (Completed) FR (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003936-50 Sponsor Protocol Number: 28063 Start Date*: 2008-03-10
    Sponsor Name:Merck Serono International S.A.
    Full Title: Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres...
    Medical condition: Esclerosis múltiple recidivante Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) NL (Completed) BE (Completed) SE (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) LT (Restarted) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001776-36 Sponsor Protocol Number: CAEB071B2201 Start Date*: 2009-02-13
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Estudio multicéntrico, aleatorizado que evalúa la eficacia, seguridad, tolerabilidad y farmacocinética de AEB071 combinado con tacrolimus o micofenolato mofetil (MMF) frente a un régimen control ba...
    Medical condition: Trasplante hepático en pacientes de novo
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 10:57:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA